[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Pan Q, Luo X, Chegini N: microRNA 21: response to hormonal therapies and regulatory function in leiomyoma, transformed leiomyoma and leiomyosarcoma cells. Mol Hum Reprod; 2010 Mar;16(3):215-27
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] microRNA 21: response to hormonal therapies and regulatory function in leiomyoma, transformed leiomyoma and leiomyosarcoma cells.
  • The results indicated that miR-21 is over-expressed in leiomyomas with specific elevation during the secretory phase of the menstrual cycle and in women who received Depo-Provera and oral contraceptives, but reduced due to GnRHa therapy (P < 0.05).
  • Bioinformatic analysis of microarray gene expression profiles previously obtained from the above cohorts, and myometrial smooth muscle cells (MSMC) and leiomyoma smooth muscle cells (LSMC) treated with GnRHa, transforming growth factor (TGF)-beta and TGF-beta receptor type II (TGF-betaRII) antisense oligomer, indicated that a number of miR-21-predicted target genes were co-expressed and differentially regulated in these cohorts.
  • Gain- and loss-of-function of miR-21 in MSMC, LSMC, transformed LSMC and leiomyosarcoma cell line (SKLM-S1) resulted in differential expression of many genes, including some of the miR-21-predicted/validated target genes, PTEN, PDCD4 and E2F1, and TGF-betaRII, in a cell-specific manner.
  • We concluded that miR-21 is aberrantly expressed and hormonally regulated in leiomyomas where, through functional interaction with ovarian steroids and the TGF-beta signaling pathway, either directly or indirectly regulates a number of genes whose products are critical in leiomyoma growth and regression as well as their potential cellular transformation.

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2000 Oct 5;276(3):930-9 [11027571.001]
  • [Cites] Hum Reprod Update. 2001 Jan-Feb;7(1):8-14 [11212080.001]
  • [Cites] Mol Hum Reprod. 2002 Dec;8(12):1071-8 [12468639.001]
  • [Cites] Endocrinology. 2005 Mar;146(3):1074-96 [15604208.001]
  • [Cites] Endocrinology. 2005 Mar;146(3):1097-118 [15604209.001]
  • [Cites] Mol Hum Reprod. 2005 Jul;11(7):489-94 [16123076.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11276-81 [16357132.001]
  • [Cites] J Soc Gynecol Investig. 2006 Feb;13(2):136-44 [16443508.001]
  • [Cites] Fertil Steril. 2006 Feb;85(2):462-7 [16595228.001]
  • [Cites] Mol Hum Reprod. 2006 Apr;12(4):245-56 [16571622.001]
  • [Cites] Exp Lung Res. 2006 May;32(5):201-14 [16908447.001]
  • [Cites] Oncogene. 2006 Oct 9;25(46):6156-62 [17028594.001]
  • [Cites] Oncogene. 2006 Oct 9;25(46):6163-9 [17028595.001]
  • [Cites] Oncogene. 2006 Oct 9;25(46):6202-10 [17028600.001]
  • [Cites] Oncogene. 2006 Oct 5;25(45):6101-12 [16682950.001]
  • [Cites] Steroids. 2006 Nov;71(11-12):960-5 [16935316.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Apr;46(4):336-47 [17243163.001]
  • [Cites] Oncogene. 2007 Apr 26;26(19):2799-803 [17072344.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6031-43 [17616659.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):647-58 [17681183.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8699-707 [17875710.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):8994-9000 [17908999.001]
  • [Cites] Reprod Biol Endocrinol. 2007;5:34 [17716379.001]
  • [Cites] Cell Signal. 2008 Jan;20(1):50-9 [17881189.001]
  • [Cites] Mol Cancer. 2007;6:60 [17894887.001]
  • [Cites] J Biol Chem. 2008 Jan 11;283(2):1026-33 [17991735.001]
  • [Cites] Bioinformatics. 2008 Feb 1;24(3):303-8 [18055479.001]
  • [Cites] Cell Res. 2008 Mar;18(3):350-9 [18270520.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):272-86 [18328430.001]
  • [Cites] J Cell Mol Med. 2008 Jan-Feb;12(1):227-40 [18182067.001]
  • [Cites] Hum Gene Ther. 2008 Jan;19(1):17-26 [18211225.001]
  • [Cites] Oncogene. 2008 Apr 3;27(15):2128-36 [17968323.001]
  • [Cites] Mol Cancer Res. 2008 Apr;6(4):663-73 [18403645.001]
  • [Cites] J Mol Biol. 2008 May 2;378(3):492-504 [18384814.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2A):907-11 [18507035.001]
  • [Cites] Fertil Steril. 2008 Jun;89(6):1771-6 [17765232.001]
  • [Cites] Nature. 2008 Jul 3;454(7200):56-61 [18548003.001]
  • [Cites] J Biol Chem. 2008 Jul 11;283(28):19593-602 [18482992.001]
  • [Cites] Oncogene. 2008 Jul 17;27(31):4373-9 [18372920.001]
  • [Cites] Mol Biol Cell. 2008 Aug;19(8):3272-82 [18508928.001]
  • [Cites] Mol Cell Biol. 2008 Sep;28(17):5369-80 [18591254.001]
  • [Cites] Cardiovasc Res. 2008 Sep 1;79(4):562-70 [18511432.001]
  • [Cites] Am J Pathol. 2008 Sep;173(3):856-64 [18688024.001]
  • [Cites] Nature. 2008 Sep 4;455(7209):64-71 [18668037.001]
  • [Cites] Nature. 2008 Sep 4;455(7209):58-63 [18668040.001]
  • [Cites] Semin Reprod Med. 2008 Nov;26(6):500-14 [18951332.001]
  • [Cites] Cancer Biol Ther. 2008 Oct;7(10):1694-9 [18769113.001]
  • [Cites] J Gastrointest Surg. 2008 Dec;12(12):2171-6 [18642050.001]
  • [Cites] Oncogene. 2009 Jan 8;28(1):73-84 [18850008.001]
  • [Cites] J Cell Mol Med. 2009 Jan;13(1):39-53 [19175699.001]
  • [Cites] Nucleic Acids Res. 2009 May;37(8):2584-95 [19264808.001]
  • [RetractionIn] Mol Hum Reprod. 2012 Dec;18(12):613 [23097499.001]
  • (PMID = 19906824.001).
  • [ISSN] 1460-2407
  • [Journal-full-title] Molecular human reproduction
  • [ISO-abbreviation] Mol. Hum. Reprod.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R03HD58779; United States / NICHD NIH HHS / HD / R01 HD058664-01A1; United States / NICHD NIH HHS / HD / R01HD37432; United States / NICHD NIH HHS / HD / R01HD58664; United States / NICHD NIH HHS / HD / R01 HD037432; United States / NICHD NIH HHS / HD / HD058779-01A1; United States / NICHD NIH HHS / HD / R01 HD037432-09; United States / NICHD NIH HHS / HD / HD058664-01A1; United States / NICHD NIH HHS / HD / R01 HD058664; United States / NICHD NIH HHS / HD / R03 HD058779-01A1; United States / NICHD NIH HHS / HD / HD037432-09; United States / NICHD NIH HHS / HD / R03 HD058779
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Retracted Publication
  • [Publication-country] England
  • [Chemical-registry-number] 0 / E2F1 Transcription Factor; 0 / E2F1 protein, human; 0 / MIRN21 microRNA, human; 0 / MicroRNAs; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta; 33515-09-2 / Gonadotropin-Releasing Hormone; 79561-22-1 / LHRH, Ala(6)-Gly(10)-ethylamide-; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ PMC2816170
  •  go-up   go-down


2. Kim K, Choi SC, Ryu SY, Kim JW, Kang SB: Major clinical research advances in gynecologic cancer 2008. J Gynecol Oncol; 2008 Dec;19(4):209-17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For uterine cancer, optimal method of adjuvant radiotherapy in intermediate-risk patients, extent of lymph node dissection, outcome of robot-assisted staging surgery, new standard chemotherapy regimen for leiomyosarcoma were selected.
  • For ovarian cancer, recent changes in adjuvant therapy, feasibility of neoadjuvant chemotherapy, prediction of optimal secondary cytoreduction, studies on new biomarkers, advances in screening and treatment of women with BRCA mutations were included.
  • For other cancers, the safety of sentinel lymph node dissection in vulvar cancer and chemotherapy regimens for low-risk gestational trophoblastic tumors were reviewed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Obstet Gynaecol. 1990 Oct;97(10):922-9 [2223684.001]
  • [Cites] Semin Oncol. 1975 Sep;2(3):267-76 [827024.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):744-51 [14984936.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):740-3 [14984935.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):686-90 [14966092.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jul-Aug;13(4):522-7 [12911732.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3695-700 [12839961.001]
  • [Cites] Gynecol Oncol. 2003 Jul;90(1):163-9 [12821358.001]
  • [Cites] J Natl Cancer Inst. 2003 Jan 15;95(2):113-25 [12529344.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2824-31 [12065559.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):106-15 [10623700.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1502-7 [18538498.001]
  • [Cites] Gynecol Oncol. 2008 Nov;111(2):282-8 [18804850.001]
  • [Cites] Gynecol Oncol. 2008 Nov;111(2):213-20 [18774597.001]
  • [Cites] Gynecol Oncol. 2008 Sep;110(3 Suppl 2):S25-8 [18501409.001]
  • [Cites] Gynecol Oncol. 2008 Jun;109(3):323-8 [18394689.001]
  • [Cites] Gynecol Oncol. 2008 Jun;109(3):329-34 [18534250.001]
  • [Cites] Gynecol Oncol. 2008 Apr;109(1):11-8 [18304622.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):884-9 [18281661.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):402-8 [18061248.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):486-91 [17762576.001]
  • [Cites] Lancet. 2007 Jun 30;369(9580):2161-70 [17602732.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1915-27 [17494925.001]
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):211-7 [17239941.001]
  • [Cites] Cancer. 2007 Feb 15;109(4):685-91 [17219441.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):1070-6 [16875720.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):807-13 [16837027.001]
  • [Cites] Ann Surg Oncol. 2006 Dec;13(12):1702-10 [17009163.001]
  • [Cites] Br J Cancer. 2006 Dec 4;95(11):1459-66 [17117182.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):155-9 [16545437.001]
  • [Cites] Cancer. 2006 May 1;106(9):1933-9 [16572412.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:30-4 [16515564.001]
  • [Cites] Oncologist. 2005 Sep;10(8):623-31 [16177286.001]
  • [Cites] Lancet Oncol. 2005 May;6(5):271-8 [15863374.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1757-65 [15541448.001]
  • [Cites] Gynecol Oncol. 1997 Mar;64(3):411-7 [9062142.001]
  • [Cites] Semin Oncol. 1996 Oct;23(5 Suppl 12):40-7 [8941409.001]
  • [Cites] Ann Oncol. 1995 Nov;6(9):887-93 [8624291.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2654-66 [7989941.001]
  • [Cites] Obstet Gynecol. 1992 Apr;79(4):490-7 [1553164.001]
  • [Cites] Lancet. 2000 Apr 22;355(9213):1404-11 [10791524.001]
  • (PMID = 19471658.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676488
  • [Keywords] NOTNLM ; Biomedical research / Gynecology / Urogenital neoplasms
  •  go-up   go-down


3. Skubitz KM, Pambuccian S, Manivel JC, Skubitz AP: Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors. J Transl Med; 2008 May 06;6:23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors.
  • The heterogeneity that soft tissue sarcomas (STS) exhibit in their clinical behavior, even within histological subtypes, complicates patient care.
  • Morphologic features are generally good predictors of biologic behavior, however, metastatic propensity, tumor growth, and response to chemotherapy may be determined by gene expression patterns that do not correlate well with morphology.
  • We have reported gene expression patterns that distinguish two subgroups of clear cell renal carcinoma (ccRCC), and other gene expression patterns that distinguish heterogeneity of serous ovarian carcinoma (OVCA) and aggressive fibromatosis (AF).
  • In this study, gene expression in 53 samples of STS and AF [including 16 malignant fibrous histiocytoma (MFH), 9 leiomyosarcoma, 12 liposarcoma, 4 synovial sarcoma, and 12 samples of AF] was determined at Gene Logic Inc. (Gaithersburg, MD) using Affymetrix GeneChip U_133 arrays containing approximately 40,000 genes/ESTs.
  • In addition, several genes that are targets of some anti-tumor drugs were found to be differentially expressed in particular subsets of STS.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1984 Feb 1;53(3):530-41 [6692258.001]
  • [Cites] J Lab Clin Med. 2004 Aug;144(2):78-91 [15322502.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):306-9 [3719523.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):817-23 [3338039.001]
  • [Cites] Cancer. 1988 Sep 1;62(5):994-8 [3409180.001]
  • [Cites] Am J Physiol. 1992 Dec;263(6 Pt 1):L627-33 [1476204.001]
  • [Cites] Ann N Y Acad Sci. 1992 Dec 4;667:101-11 [1309029.001]
  • [Cites] Mod Pathol. 1995 Sep;8(7):705-10 [8539226.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] Am J Pathol. 1997 Aug;151(2):329-34 [9250146.001]
  • [Cites] J Surg Oncol. 1999 Oct;72(2):77-82 [10518103.001]
  • [Cites] Cancer Immun. 2005 Feb 1;5:2 [15683221.001]
  • [Cites] Cancer Invest. 2005;23(2):105-18 [15813502.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):701-11 [16107623.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9226-35 [16230383.001]
  • [Cites] Histopathology. 2006 Jan;48(1):22-31 [16359534.001]
  • [Cites] Histopathology. 2006 Jan;48(1):51-62 [16359537.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1195-203 [16505440.001]
  • [Cites] J Lab Clin Med. 2006 May;147(5):250-67 [16697773.001]
  • [Cites] Transl Res. 2006 Nov;148(5):223-48 [17145569.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Apr;5(4):364-99 [17442230.001]
  • [Cites] Mayo Clin Proc. 2007 Nov;82(11):1409-32 [17976362.001]
  • [Cites] Annu Rev Pathol. 2006;1:119-50 [18039110.001]
  • [Cites] Cancer Cell. 2007 Dec;12(6):514-27 [18068629.001]
  • [Cites] Oncogene. 1999 Nov 11;18(47):6615-20 [10597266.001]
  • [Cites] J Clin Pathol. 1999 Sep;52(9):695-6 [10655994.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Int J Cancer. 2001 Mar 20;95(2):102-7 [11241320.001]
  • [Cites] Nat Med. 2001 Jun;7(6):673-9 [11385503.001]
  • [Cites] Breast Cancer Res. 2001;3(6):365-72 [11737887.001]
  • [Cites] Lab Invest. 2002 Jan;82(1):97-103 [11796830.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):39-46 [11823972.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1301-7 [11965276.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6973-8 [11983872.001]
  • [Cites] J Lab Clin Med. 2003 May;141(5):297-308 [12761473.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):1941-56 [12796356.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):691-700 [12875988.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):1029-38 [12942572.001]
  • [Cites] J Lab Clin Med. 2004 Feb;143(2):89-98 [14966464.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4776-83 [15269152.001]
  • [Cites] Cancer Immun. 2004 Aug 9;4:7 [15298487.001]
  • [Cites] J Clin Invest. 1985 Jan;75(1):11-8 [3965498.001]
  • (PMID = 18460215.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA106878-03; United States / NCI NIH HHS / CA / R01 CA106878; United States / NCI NIH HHS / CA / R01 CA106878-03; United States / NCI NIH HHS / CA / R01CA106878
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC2412854
  •  go-up   go-down


Advertisement
4. Bailey HH, Alberti DB, Thomas JP, Mulkerin DL, Binger KA, Gottardis MM, Martell RE, Wilding G: Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors. Clin Cancer Res; 2007 Jun 15;13(12):3623-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Twenty-six patients received 94 courses (one course, 21 days) of study treatment.
  • Objective partial responses were observed in patients with pretreated head and neck, ovarian, and hormone-refractory prostate carcinomas, and leiomyosarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Benzodiazepines / administration & dosage. Imidazoles / administration & dosage. Neoplasms / drug therapy. Paclitaxel / administration & dosage

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17510207.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01RR03186
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine; 0 / Imidazoles; 12794-10-4 / Benzodiazepines; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


5. Mayerhofer K, Lozanov P, Bodner K, Bodner-Adler B, Mayerhofer-Gallenbacher N, Hudelist G, Czerwenka K: Immunohistochemical analysis of a primary ovarian leiomyosarcoma. Case report. Anticancer Res; 2003 Jul-Aug;23(4):3433-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of a primary ovarian leiomyosarcoma. Case report.
  • BACKGROUND: Primary ovarian leiomyosarcoma is an extremely rare malignant smooth muscle neoplasm.
  • We report a case of a primary leiomyosarcoma of the ovary managed at our institution.
  • CASE REPORT: Surgical exploration in a 71-year-old woman revealed a large left adnexal tumor and one separate metastatic implant in one part of the omentum, being classified as a primary ovarian leiomyosarcoma stage III C.
  • The patient was treated with an adjuvant chemotherapy regimen consisting of cisplatin and ifosfamide.
  • CONCLUSION: Until recently, prognostic parameters in ovarian leiomyosarcoma have still not been identified.
  • [MeSH-major] Leiomyosarcoma / metabolism. Ovarian Neoplasms / metabolism

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12926085.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Endothelial Growth Factors; 0 / Intercellular Signaling Peptides and Proteins; 0 / Ki-67 Antigen; 0 / Lymphokines; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


6. Nicòtina PA, Antico F, Caruso C, Triolo O: Primary ovarian leiomyosarcoma. Proliferation rate and survival. Eur J Gynaecol Oncol; 2004;25(4):515-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary ovarian leiomyosarcoma. Proliferation rate and survival.
  • OBJECTIVE: A case of Stage IIA primary ovarian leiomyosarcoma (LMS) with an unfavorable outcome 24 months after total abdominal hysterectomy with bilateral salpingo-oophorectomy, despite chemotherapy treatment, is described.
  • Immunohistology was also carried out to reveal some intermediate-type filamentous proteins, as histogenetic markers, and the MIB1 monoclonal antibody was used to assess the percent of MIB1-positive nuclei (MIB1 labeling index).
  • RESULTS: The histologic findings and immunohistology of the assayed intermediate filamentous proteins substantiated a diagnosis of LMS, with associated coagulation necrosis and not rare mitotic figures.
  • CONCLUSIONS: The proliferation indices in the described variant of ovarian LMS, denote a fast growing malignancy.
  • [MeSH-major] Leiomyosarcoma / pathology. Leiomyosarcoma / surgery. Neoplasm Invasiveness / pathology. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15285319.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


7. Khabir A, Boudawara T, Ayadi L, Kharrat M, Kharrat M, Beyrouti I, Jlidi R: [Epithelioid bilateral ovarian leiomyosarcoma: a study]. Ann Pathol; 2003 Feb;23(1):47-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epithelioid bilateral ovarian leiomyosarcoma: a study].
  • [Transliterated title] Léiomyosarcome ovarien bilatéral de type épithélioïde: une observation.
  • Primary ovarian leiomyosarcoma is extremely rare and generally affects post menopausal women.
  • Its histogenesis is not clear its prognosis seems to be improved by radical surgery and adjuvant therapy.
  • A diagnosis of bilateral ovarian epithelioid leiomyosarcoma was made on pathological examination with immunohistochemistry.
  • Adjuvant chemotherapy was given.
  • [MeSH-major] Leiomyosarcoma / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Fallopian Tubes / surgery. Female. Humans. Hysterectomy. Immunohistochemistry. Liver Neoplasms / secondary. Liver Neoplasms / ultrasonography. Menopause. Middle Aged. Ovariectomy. Prognosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12743499.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


8. Villalona-Calero MA, Eckhardt SG, Weiss G, Hidalgo M, Beijnen JH, van Kesteren C, Rosing H, Campbell E, Kraynak M, Lopez-Lazaro L, Guzman C, Von Hoff DD, Jimeno J, Rowinsky EK: A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res; 2002 Jan;8(1):75-85
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antitumor activity was noted in three patients with leiomyosarcoma and primary peritoneal and ovarian carcinomas.
  • The pharmacokinetics of ET-743 were dose independent, and drug accumulation over the 5 days of treatment was modest, with the ratio of the area under the plasma-versus-time curve on day 5 to that on day 1 averaging 2.05.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alanine Transaminase / metabolism. Area Under Curve. Aspartate Aminotransferases / metabolism. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Liver / drug effects. Male. Maximum Tolerated Dose. Middle Aged. Tetrahydroisoquinolines. Time Factors. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11801542.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR01346
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Isoquinolines; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


9. Bodner K, Bodner-Adler B, Czerwenka K, Hudelist G, Kimberger O, Leodolter S, Mayerhofer K: Bcl-2 expression in a primary leiomyosarcoma of the ovary: a case report. Wien Klin Wochenschr; 2003 Mar 31;115(5-6):191-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2 expression in a primary leiomyosarcoma of the ovary: a case report.
  • BACKGROUND: Primary ovarian leiomyosarcoma is an extremely rare malignant smooth-muscle neoplasm with fewer than 30 documented cases worldwide.
  • Immunohistochemically, ovarian leiomyosarcomas are characterized by the expression of alpha-smooth muscle actin (alpha-SMA).
  • Until recently, no report investigated the role of bcl-2 expression in primary ovarian leiomyosarcoma.
  • We report the management and an immunohistochemical analysis of bcl-2 in a patient with primary leiomyosarcoma of the ovary.
  • Surgical exploration revealed a large left adnexal mass that had developed from the left ovary and infiltrated one part of the omentum adherent to the left adnexa.
  • According to the FIGO staging system for ovarian cancer, the tumor was classified as a primary ovarian leiomyosarcoma stage III C, and the patient was treated with an adjuvant chemotherapy regimen consisting of cisplatin and ifosfamide.
  • Two days after the third cycle of cisplatin/ifosfamid she developed an apoplexy spontaneously and chemotherapy was therefore discontinued.
  • CONCLUSIONS: Beside the routine histological and immunohistochemical characteristics of primary ovarian leiomyosarcoma, strong staining for bcl-2 was detected.
  • In order to understand more about the nature and the behaviour of this highly malignant neoplasm and to be able to improve the treatment, the prognostic value of bcl-2 has to be investigated in additional studies.
  • [MeSH-major] Leiomyosarcoma / pathology. Ovarian Neoplasms / pathology. Proto-Oncogene Proteins c-bcl-2 / analysis
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Fatal Outcome. Female. Humans. Ovariectomy. Ovary / pathology

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Postgrad Med. 1993 Jul-Sep;39(3):151-3 [8051647.001]
  • [Cites] Gynecol Oncol. 1987 Sep;28(1):116-20 [3308653.001]
  • [Cites] Br J Cancer. 1995 May;71(5):1003-7 [7734290.001]
  • [Cites] Exp Cell Res. 1991 Aug;195(2):277-83 [2070813.001]
  • [Cites] Gynecol Oncol. 1993 Mar;48(3):389-93 [8462904.001]
  • [Cites] Am J Pathol. 1996 Dec;149(6):1941-52 [8952529.001]
  • [Cites] N Engl J Med. 1993 Sep 2;329(10):690-4 [8393963.001]
  • [Cites] Arch Pathol Lab Med. 1991 Sep;115(9):941-5 [1929791.001]
  • [Cites] J Cell Biol. 1994 Jan;124(1-2):1-6 [8294493.001]
  • [Cites] Br J Cancer. 1999 Jul;80(10):1658-64 [10408415.001]
  • [Cites] Cell. 1991 Jun 28;65(7):1097-8 [1648446.001]
  • [Cites] Eur J Gynaecol Oncol. 1999;20(3):172-3 [10410877.001]
  • [Cites] Pathol Int. 2000 Feb;50(2):162-5 [10792777.001]
  • [Cites] J Obstet Gynaecol Res. 2000 Dec;26(6):401-7 [11152324.001]
  • [Cites] J Natl Cancer Inst. 1994 Apr 6;86(7):499-504 [8133533.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):293-9 [8989276.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jul;83(14):5214-8 [3523487.001]
  • [Cites] Int J Gynecol Cancer. 2002 Nov-Dec;12(6):745-8 [12445253.001]
  • [Cites] Eur J Gynaecol Oncol. 1998;19(3):257-61 [9641226.001]
  • [Cites] Gynecol Oncol. 1997 Sep;66(3):519-25 [9299270.001]
  • [Cites] Gynecol Oncol. 1987 Feb;26(2):183-92 [3643159.001]
  • [Cites] Am J Obstet Gynecol. 1972 Jan 15;112(2):183-91 [4109398.001]
  • (PMID = 12741081.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


10. Pearl ML, Inagami M, McCauley DL, Valea FA, Chalas E, Fischer M: Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecological sarcomas. Int J Gynecol Cancer; 2002 Nov-Dec;12(6):745-8
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecological sarcomas.
  • The results of treatment with MAID were disappointing.
  • Overall, the response rate was 9% with one complete response and one partial response (both in patients with uterine leiomyosarcoma).
  • We did not observe any responses among the patients with carcinosarcomas of either ovarian or uterine origin.
  • It remains to be established if any combination chemotherapy regimen is better than single agent treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Genital Neoplasms, Female / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinosarcoma / drug therapy. Carcinosarcoma / mortality. Carcinosarcoma / pathology. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Ifosfamide / administration & dosage. Leiomyosarcoma / drug therapy. Leiomyosarcoma / mortality. Leiomyosarcoma / pathology. Medical Records. Mesna / administration & dosage. Middle Aged. Neoplasm Staging. New York. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology. Retrospective Studies. Survival Analysis. Treatment Outcome. Uterine Neoplasms / drug therapy. Uterine Neoplasms / mortality. Uterine Neoplasms / pathology. Vulvar Neoplasms / drug therapy. Vulvar Neoplasms / mortality. Vulvar Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12445253.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide; MAID protocol
  •  go-up   go-down


11. Kaleli S, Calay Z, Ceydeli N, Aydýnlý K, Kösebay D: A huge abdominal mass mimicking ovarian cancer: p53-negative but aneuploid myxoid leiomyosarcoma of the uterus. Eur J Obstet Gynecol Reprod Biol; 2001 Dec 10;100(1):96-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A huge abdominal mass mimicking ovarian cancer: p53-negative but aneuploid myxoid leiomyosarcoma of the uterus.
  • OBJECTIVE: Less than 20 myxoid leiomyosarcoma cases were reported in literature.
  • Since, these tumors are very rare and may exhibit highly malignant behavior despite their low mitotic index, clinical course and optimum type of therapy of myxoid variant of leiomyosarcoma were not well understood.
  • The goal of this report is to contribute the better understanding of this rare type of tumor.
  • Laparotomy was performed and frozen section diagnosis was low-grade uterine leiomyosarcoma.
  • No chemotherapy was performed after surgical therapy.
  • RESULTS: Final histopathological diagnosis was uterine myxoid leiomyosarcoma.
  • The patient tolerated well the operation and she is alive and free of disease after 24 months of primary surgical treatment.
  • CONCLUSION: Uterine myxoid leiomyosarcoma may present a huge abdominal cystic mass and can be treated successfully with surgery alone.
  • [MeSH-major] Aneuploidy. Leiomyoma / diagnosis. Ovarian Neoplasms. Tumor Suppressor Protein p53 / analysis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Adult. DNA / analysis. Diagnosis, Differential. Female. Flow Cytometry. Humans


12. Sultana N, Pikaart DP, Ahmad S, DeNardis SA, Finkler NJ: Paraovarian leiomyosarcoma with scalp metastasis: a case report. Eur J Gynaecol Oncol; 2009;30(5):566-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraovarian leiomyosarcoma with scalp metastasis: a case report.
  • PURPOSE: Leiomyosarcoma is a rare neoplasm.
  • There is paucity of literature in regards to paraovarian leiomyosarcoma with metastases to the scalp.
  • We present a 72-year-old woman with metastases to the scalp from a primary paraovarian high grade leiomyosarcoma.
  • She presented 18 months later with metastatic high-grade leiomyosarcoma to the scalp.
  • CONCLUSION: High-grade leiomyosarcoma is known for its resistance to chemotherapy, radiation therapy, and propensity for hematological dissemination with an overall poor prognosis.
  • [MeSH-major] Head and Neck Neoplasms / secondary. Leiomyosarcoma / secondary. Ovarian Neoplasms / pathology. Scalp. Skin Neoplasms / secondary

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19899418.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


13. Ahuja S, Gaunt M, Crawford R: The use of Palma's procedure in the salvage therapy for a leiomyosarcoma of the right pelvic sidewall: an intraoperative multidisciplinary approach. Int J Gynecol Cancer; 2005 Jan-Feb;15(1):175-9
Genetic Alliance. consumer health - Leiomyosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of Palma's procedure in the salvage therapy for a leiomyosarcoma of the right pelvic sidewall: an intraoperative multidisciplinary approach.
  • Leiomyosarcomas of the ovary and broad ligament are relatively rare.
  • Less than 50 cases of primary ovarian and broad ligament leiomyosarcomas have been reported.
  • It is difficult to determine the exact role of surgery, chemotherapy, and radiotherapy in the management of these tumors.
  • So far, no cases of ovarian or broad ligament leiomyosarcomas have been reported where primary surgery for the sarcoma had to be combined with a Palma's procedure.
  • We report a case of a right pelvic sidewall leiomyosarcoma with involvement of 10 cm of the right external iliac vein.
  • Resection of the pelvic mass was carried out and a Palma's procedure was performed by the vascular surgeon.
  • Histology reported an incompletely excised high-grade leiomyosarcoma.
  • Chemotherapy was given postoperatively.
  • [MeSH-major] Genital Neoplasms, Female / surgery. Iliac Vein. Leiomyosarcoma / surgery. Vascular Neoplasms / surgery. Vascular Surgical Procedures / methods
  • [MeSH-minor] Combined Modality Therapy. Female. Gynecologic Surgical Procedures. Humans. Middle Aged. Patient Care Team. Pelvis. Salvage Therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670315.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Mariani L, Quattrini M, Galati M, Dionisi B, Piperno G, Modafferi F, Sbiroli C: Primary leiomyosarcoma of the fallopian tube: a case report. Eur J Gynaecol Oncol; 2005;26(3):333-5
Genetic Alliance. consumer health - Leiomyosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary leiomyosarcoma of the fallopian tube: a case report.
  • A primary leiomyosarcoma (LMS) arising from the left fallopian tube in a perimenopausal 48-year-old woman is reported.
  • The diagnosis is usually made at the time of laparotomy for a pelvic or adnexal mass or other gynaecological indications.
  • As in ovarian neoplasms, the mainstay of treatment is represented by debulking surgery consisting of total abdominal hysterectomy, bilateral salpingo-oophorectomy, random biopsies, peritoneal washing and excision of all the abdominal tumour masses.
  • The role of adjuvant radio- or chemotherapy still remains unsolved.
  • [MeSH-major] Fallopian Tube Neoplasms / diagnosis. Leiomyosarcoma / diagnosis
  • [MeSH-minor] Female. Gynecologic Surgical Procedures. Humans. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991540.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


15. Vogl TJ, Zangos S, Eichler K, Selby JB, Bauer RW: Palliative hepatic intraarterial chemotherapy (HIC) using a novel combination of gemcitabine and mitomycin C: results in hepatic metastases. Eur Radiol; 2008 Mar;18(3):468-76
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative hepatic intraarterial chemotherapy (HIC) using a novel combination of gemcitabine and mitomycin C: results in hepatic metastases.
  • To evaluate repeated hepatic intraarterial chemotherapy (HIC) as a palliative treatment option for unresectable cholangiocarcinoma and liver metastases of various origins that were progressive under systemic chemotherapy.
  • Treated tumor entities were colorectal carcinoma (CRC) (n = 12), breast cancer (BC) (n = 12), cholangiocarcinoma (CCC) (n = 10), pancreatic (n = 4), ovarian (n = 3), gastric, cervical, papillary (each n = 2), prostate, esophageal carcinoma, leiomyosarcoma (each n = 1), cancer of unknown primacy (CUP) (n = 5).
  • All patients tolerated the treatment well without any major side effects or complications.
  • HIC with gemcitabine/mitomycin is a safe, minimally invasive, palliative treatment for hepatic metastases that are progressive under systemic chemotherapy.
  • The treatment yields respectable tumor control rates in CRC and BC patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Palliative Care
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Breast Neoplasms / pathology. Cholangiocarcinoma / pathology. Colorectal Neoplasms / pathology. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Injections, Intra-Arterial. Male. Middle Aged. Mitomycin / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 2:ii93-6 [15958484.001]
  • [Cites] Am J Surg. 2003 Feb;185(2):158-64 [12559448.001]
  • [Cites] Oncology. 2005;69 Suppl 3:17-24 [16301832.001]
  • [Cites] J Natl Cancer Inst. 1988 Mar 16;80(2):84-9 [3278123.001]
  • [Cites] Breast Cancer Res Treat. 2000 Feb;59(3):271-8 [10832597.001]
  • [Cites] Eur J Surg Oncol. 2000 Apr;26(3):209-12 [10753531.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23 (22):4888-96 [16009951.001]
  • [Cites] J Vasc Interv Radiol. 2005 Mar;16(3):353-61 [15758131.001]
  • [Cites] Eur Radiol. 2007 Apr;17(4):1025-34 [16944163.001]
  • [Cites] Acta Oncol. 2003;42(4):263-75 [12899497.001]
  • [Cites] Drugs. 1997 Sep;54(3):447-72 [9279506.001]
  • [Cites] Eur J Surg Oncol. 2005 Nov;31(9):932-41 [15979268.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1402-7 [15726542.001]
  • [Cites] Zentralbl Chir. 1995;120(10):786-90 [7502593.001]
  • [Cites] J Surg Oncol. 2005 Aug 1;91(2):97-101 [16028279.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jul;56(1):67-78 [10517344.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1395-403 [16505413.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Nov;132(11):745-55 [16858591.001]
  • [Cites] Breast Cancer Res Treat. 2006 Mar;96(1):53-62 [16319993.001]
  • [Cites] Eur J Radiol. 2002 Jan;41(1):42-8 [11750151.001]
  • [Cites] Oncologist. 2004;9(1):43-57 [14755014.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;33 Suppl:S142-4 [8137476.001]
  • [Cites] Ther Umsch. 2006 Apr;63(4):255-61 [16689456.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):4881-7 [16009952.001]
  • [Cites] Eur J Surg Oncol. 2006 Nov;32(9):922-7 [16822644.001]
  • [Cites] J Surg Oncol. 1994 Jan;55(1):26-31; discussion 32 [8289448.001]
  • [Cites] Cancer. 1989 Dec 1;64(11):2203-6 [2529960.001]
  • [Cites] Oncology (Williston Park). 1996 Nov;10(11 Suppl):131-5 [8953600.001]
  • [Cites] Recent Results Cancer Res. 1983;86:1-12 [6647987.001]
  • [Cites] Z Gastroenterol. 2006 Jul;44(7):587-98 [16823700.001]
  • [Cites] Jpn J Clin Oncol. 1999 Jan;29(1):23-7 [10073147.001]
  • [Cites] Ann R Coll Surg Engl. 2005 May;87(3):167-70 [15901375.001]
  • [Cites] Zentralbl Chir. 1998;123 Suppl 5:159-61 [10063604.001]
  • [Cites] Lancet. 2005 Oct 8;366(9493):1303-14 [16214602.001]
  • [Cites] Oncologist. 2005;10 Suppl 3:20-9 [16368868.001]
  • [Cites] Cancer Treat Rep. 1980 Jan;64(1):31-40 [6155210.001]
  • [Cites] Eur J Cancer. 1998 Jun;34(7):977-86 [9849443.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] ANZ J Surg. 2004 Sep;74(9):781-7 [15379811.001]
  • (PMID = 17938935.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 50SG953SK6 / Mitomycin; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


16. Kobayashi Y, Tozawa A, Okuma Y, Kiguchi K, Ishizuka B: Complete remission with intraperitoneal cisplatin followed by prolonged oral etoposide in a stage IIIc primary leiomyosarcoma of the fallopian tube patient. J Obstet Gynaecol Res; 2010 Aug;36(4):894-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission with intraperitoneal cisplatin followed by prolonged oral etoposide in a stage IIIc primary leiomyosarcoma of the fallopian tube patient.
  • Leiomyosarcoma (LMS) of the fallopian tube is exceedingly uncommon.
  • Because of elevated serum lactate dehydrogenase and CA125 as well as the findings of pelvic magnetic resonance imaging and computerized tomography, the patient was suspected to have ovarian cancer.
  • [MeSH-major] Cisplatin / therapeutic use. Etoposide / therapeutic use. Fallopian Tube Neoplasms / drug therapy. Leiomyosarcoma / drug therapy
  • [MeSH-minor] Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Female. Humans. Injections, Intraperitoneal. Neoplasm Staging. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20666965.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


17. Carter NJ, Keam SJ: Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer. Drugs; 2010 Feb 12;70(3):355-76
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.
  • It is indicated in the EU and many other countries for use in patients with advanced soft-tissue sarcoma (STS) who have progressed despite receiving previous treatment with anthracyclines and ifosfamide or in those who are unable to receive these agents.
  • It is also approved in the EU in combination with pegylated liposomal doxorubicin for the treatment of platinum-sensitive, recurrent ovarian cancer.
  • In addition, trabectedin holds orphan drug status for the treatment of advanced, recurrent STS in the US, Switzerland and Korea, and for the treatment of advanced, recurrent ovarian cancer in the US and Switzerland.
  • Clinical trials showed that intravenous trabectedin was effective in chemotherapy-experienced patients with advanced, recurrent liposarcoma or leiomyosarcoma, and results from a retrospective analysis suggest that the drug may be particularly effective in patients with advanced myxoid liposarcoma.
  • In addition, coadministration of trabectedin with pegylated liposomal doxorubicin was associated with a significantly longer progression-free survival (6 weeks) than pegylated liposomal doxorubicin monotherapy in patients with recurrent ovarian cancer after failure of first-line, platinum-based chemotherapy.
  • Results to date indicate that trabectedin is a valuable addition to the group of second-line antineoplastic agents available for the treatment of advanced, recurrent STS, and that it is a beneficial treatment for recurrent ovarian cancer after failure of first-line, platinum-based chemotherapy when administered in conjunction with pegylated liposomal doxorubicin.
  • [MeSH-major] Antineoplastic Agents, Alkylating. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dioxoles. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy. Sarcoma / drug therapy. Tetrahydroisoquinolines

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2009 Sep 1;27(25):4188-96 [19652065.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Dec;63(1):181-8 [18379785.001]
  • [Cites] Obstet Gynecol. 2006 Jun;107(6):1399-410 [16738170.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14 (20):6449-55 [18927284.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):8155-62 [16912194.001]
  • [Cites] Eur J Cancer. 2006 Jul;42(10 ):1484-90 [16737808.001]
  • [Cites] Invest New Drugs. 2006 Jan;24(1):3-14 [16379042.001]
  • [Cites] Drugs. 2002;62(8):1185-92; discussion 1193-4 [12010079.001]
  • [Cites] Toxicol Appl Pharmacol. 2008 Apr 1;228(1):17-23 [18191164.001]
  • [Cites] Mol Cancer Ther. 2009 Feb;8(2):449-57 [19190116.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23 (24):5484-92 [16110008.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):672-7 [15701855.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14 (20):6656-62 [18927308.001]
  • [Cites] Anticancer Drugs. 2005 Sep;16(8):811-5 [16096428.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):845-56 [16239904.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12 ):2305-11 [14676811.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2964-71 [15805300.001]
  • [Cites] J Clin Oncol. 2010 Jul 1;28(19):3107-14 [20516432.001]
  • [Cites] Clin Pharmacol Ther. 2008 Jan;83(1):130-43 [17597713.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5902-8 [14522916.001]
  • [Cites] Mol Biol Cell. 2008 Sep;19(9):3969-81 [18632984.001]
  • [Cites] Am J Clin Dermatol. 2008;9(4):207-17 [18572972.001]
  • [Cites] Br J Cancer. 2007 Dec 17;97(12 ):1618-24 [18000504.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Jun;62(1):135-47 [17922277.001]
  • [Cites] Eur J Cancer. 1999 Nov;35(12):1705-10 [10674017.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12 ):3377-81 [12067978.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Aug;52(2):131-8 [12783202.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):701-11 [16107623.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13062-7 [17656556.001]
  • [Cites] Drugs. 2007;67(15):2257-76 [17927287.001]
  • [Cites] Ann Oncol. 2008 Oct;19(10 ):1802-9 [18497430.001]
  • [Cites] Drugs. 2005;65(2):167-78 [15631540.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 May;59(6):825-37 [16988825.001]
  • [Cites] Eur J Cancer. 2008 Mar;44(4):609-18 [18243687.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Oct;50(4):309-19 [12357306.001]
  • [Cites] Invest New Drugs. 2010 Apr;28(2):145-55 [19238326.001]
  • [Cites] Lancet Oncol. 2007 Jul;8(7):595-602 [17586092.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):543-9 [11872347.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Apr;5(4):401-10 [17442231.001]
  • [Cites] Anticancer Agents Med Chem. 2008 Dec;8(8):886-903 [19075571.001]
  • [Cites] Mayo Clin Proc. 2007 Jun;82(6):751-70 [17550756.001]
  • [Cites] Eur J Cancer. 2008 Aug;44(12 ):1726-33 [18501589.001]
  • [Cites] Lancet Oncol. 2007 Jul;8(7):565-7 [17613417.001]
  • [Cites] Ann Oncol. 2009 Nov;20(11):1794-802 [19556318.001]
  • [Cites] Eur J Cancer. 2009 Aug;45(12 ):2116-22 [19419856.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23 (3):576-84 [15659504.001]
  • [Cites] Curr Clin Pharmacol. 2009 Jan;4(1):38-42 [19149499.001]
  • [Cites] Br J Cancer. 2008 Sep 23;99 Suppl 1:S70-2 [18813266.001]
  • [Cites] Biochem Pharmacol. 2009 May 15;77(10 ):1642-54 [19426702.001]
  • [Cites] Clin Pharmacokinet. 2007;46(10 ):867-84 [17854236.001]
  • [Cites] Curr Opin Oncol. 2006 Jul;18(4):347-53 [16721129.001]
  • [Cites] Mol Cancer Ther. 2008 May;7(5):1309-18 [18483318.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23 (9):1867-74 [15774779.001]
  • [Cites] Eur J Cancer. 2009 May;45(7):1153-61 [19114300.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):890-9 [14990645.001]
  • [Cites] Ann Oncol. 2009 Aug;20(8):1439-44 [19465423.001]
  • [Cites] Anticancer Drugs. 2005 Oct;16(9):935-43 [16162970.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12 ):4725-32 [11156226.001]
  • [Cites] Ann Oncol. 2008 May;19 Suppl 2:ii89-93 [18456783.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(13):1920-6 [12932672.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Sep;6(8):766-94 [18926089.001]
  • [Cites] Expert Opin Pharmacother. 2008 Jun;9(9):1609-18 [18518789.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1480-90 [15084621.001]
  • [Cites] Nat Prod Rep. 2009 Mar;26(3):322-37 [19240944.001]
  • [Cites] Nat Med. 2001 Aug;7(8):961-6 [11479630.001]
  • [Cites] Ann Oncol. 2008 May;19 Suppl 2:ii14-6 [18456751.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2908-11 [11555609.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10 ):3251-7 [11595721.001]
  • (PMID = 20166769.001).
  • [ISSN] 1179-1950
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Tetrahydroisoquinolines; ID0YZQ2TCP / trabectedin
  • [Number-of-references] 104
  •  go-up   go-down


18. See HT, Thomas DA, Bueso-Ramos C, Kavanagh J: Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with recurrent ovarian cancer. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:236-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with recurrent ovarian cancer.
  • The occurrence of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) has been reported after treatment with cytotoxic alkylating agent-based chemotherapy for solid tumors.
  • We report a patient with metastatic ovarian carcinoma treated with carboplatin and paclitaxel, who developed secondary acute erythroid leukemia.
  • The overall survival of patients with stage III and IV ovarian cancer has increased in the past decade.
  • The incidence and outcome of secondary leukemia in the setting of active ovarian carcinoma is reviewed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Erythroblastic, Acute / chemically induced. Liver Neoplasms / therapy. Neoplasms, Glandular and Epithelial / therapy. Ovarian Neoplasms / therapy
  • [MeSH-minor] Arm. Busulfan / administration & dosage. Carboplatin / administration & dosage. Carboplatin / adverse effects. Cytarabine / administration & dosage. Fatal Outcome. Female. Gynecologic Surgical Procedures. Humans. Idarubicin / administration & dosage. Leiomyosarcoma / surgery. Middle Aged. Neoplasm Recurrence, Local. Neoplasm, Residual. Neoplasms, Second Primary. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Reoperation. Stem Cell Transplantation. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515597.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; BG3F62OND5 / Carboplatin; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine; P88XT4IS4D / Paclitaxel; ZRP63D75JW / Idarubicin
  •  go-up   go-down


19. Carter NJ, Keam SJ: Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs; 2007;67(15):2257-76
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.
  • Intravenous trabectedin administered once every 3 weeks is approved as monotherapy in Europe for use in patients with advanced soft tissue sarcoma (STS) after failure of standard therapy with anthracyclines or ifosfamide, or who are unsuited to receive these agents.
  • It also has orphan drug status in STS in the US and in ovarian cancer in the US and Europe, and is under investigation as combination therapy in patients with recurrent ovarian cancer.
  • In clinical trials, trabectedin showed efficacy in the treatment of patients with advanced or metastatic STS, especially those with leiomyosarcoma or liposarcoma, as well as in women with platinum-sensitive advanced or recurrent ovarian cancer.
  • The introduction of trabectedin expands the currently limited range of effective treatment options for patients with advanced or metastatic STS; trabectedin also has the potential to be a beneficial treatment for advanced or recurrent ovarian cancer.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dioxoles / therapeutic use. Ovarian Neoplasms / drug therapy. Sarcoma / drug therapy. Tetrahydroisoquinolines / therapeutic use

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 1998 Sep;9(9):981-7 [9818072.001]
  • [Cites] Obstet Gynecol. 2006 Jun;107(6):1399-410 [16738170.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Mol Cancer Ther. 2005 Feb;4(2):333-42 [15713904.001]
  • [Cites] J Med Chem. 2006 Nov 16;49(23 ):6925-9 [17154523.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):8155-62 [16912194.001]
  • [Cites] Eur J Cancer. 2006 Jul;42(10 ):1484-90 [16737808.001]
  • [Cites] Invest New Drugs. 2006 Jan;24(1):3-14 [16379042.001]
  • [Cites] Drugs. 2002;62(8):1185-92; discussion 1193-4 [12010079.001]
  • [Cites] Biochem Pharmacol. 2003 Dec 15;66(12 ):2381-95 [14637196.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23 (24):5484-92 [16110008.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(2):323-33 [15661559.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):672-7 [15701855.001]
  • [Cites] Anticancer Drugs. 2005 Sep;16(8):811-5 [16096428.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12 ):2305-11 [14676811.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2964-71 [15805300.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5902-8 [14522916.001]
  • [Cites] Mol Pharmacol. 2005 Nov;68(5):1496-503 [15961672.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12 ):3893-903 [12473605.001]
  • [Cites] Eur J Cancer. 2004 Jun;40(9):1327-31 [15177491.001]
  • [Cites] Ann Oncol. 2007 Apr;18 Suppl 2:ii74-6 [17491057.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12 ):3377-81 [12067978.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Aug;52(2):131-8 [12783202.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):701-11 [16107623.001]
  • [Cites] Invest New Drugs. 2007 Feb;25(1):1-7 [16633714.001]
  • [Cites] Drugs. 2005;65(2):167-78 [15631540.001]
  • [Cites] CA Cancer J Clin. 2004 Mar-Apr;54(2):94-109 [15061599.001]
  • [Cites] Semin Oncol. 2007 Apr;34(2 Suppl 2):S1-15 [17512352.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 May;59(6):825-37 [16988825.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Oct;50(4):309-19 [12357306.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Lancet Oncol. 2007 Jul;8(7):595-602 [17586092.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):543-9 [11872347.001]
  • [Cites] Clin Cancer Res. 2010 May 1;16(9):2656-65 [20406837.001]
  • [Cites] Mayo Clin Proc. 2007 Jun;82(6):751-70 [17550756.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1610-4 [16736024.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2 Suppl 6):S12-6 [16716798.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jan-Feb;17(1):1-20 [17291226.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23 (3):576-84 [15659504.001]
  • [Cites] Int J Oncol. 2005 Dec;27(6):1605-16 [16273217.001]
  • [Cites] Ann Oncol. 2007 Apr;18 Suppl 2:ii12-4 [17491026.001]
  • [Cites] Curr Opin Oncol. 2006 Jul;18(4):347-53 [16721129.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23 (9):1867-74 [15774779.001]
  • [Cites] Curr Opin Oncol. 2007 Jul;19(4):336-40 [17545796.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):890-9 [14990645.001]
  • [Cites] Anticancer Drugs. 2005 Oct;16(9):935-43 [16162970.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12 ):4725-32 [11156226.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(13):1920-6 [12932672.001]
  • [Cites] Cancer. 2003 Aug 15;98 (4):832-40 [12910529.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1480-90 [15084621.001]
  • [Cites] Lancet. 2003 Jun 21;361(9375):2099-106 [12826431.001]
  • [Cites] Orthop Nurs. 2007 Jan-Feb;26(1):4-11; quiz 12-3 [17273099.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2908-11 [11555609.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10 ):3251-7 [11595721.001]
  • (PMID = 17927287.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Tetrahydroisoquinolines; ID0YZQ2TCP / trabectedin
  • [Number-of-references] 80
  •  go-up   go-down


20. Jha S, Chan KK, Poole CJ, Rollason TP: Pregnancy following recurrent angiosarcoma of the ovary--a case report and review of literature. Gynecol Oncol; 2005 Jun;97(3):935-7
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pregnancy following recurrent angiosarcoma of the ovary--a case report and review of literature.
  • BACKGROUND: Ovarian angiosarcomas are rare tumors which may to be distinguished from other unusual primary ovarian tumors such as clear cell carcinoma, yolk sac tumor and leiomyosarcoma on the basis of histological appearance and immunohistochemistry.
  • Angiosarcomas of the ovary occur in all age groups but are more frequent in women of child bearing age (less than 40 years).
  • Surgery and radiotherapy have been the traditional treatment modalities.
  • CASE: The case we present is the only reported long-term survivor of recurrent ovarian angiosarcoma.
  • Her initial treatment was surgical, both at presentation and relapse but since she wished conservation of fertility, radical surgery and radiotherapy were avoided and she underwent further adjuvant chemotherapy with doxorubicin and ifosfamide.
  • She remains in remission 6 years after treatment of recurrence of the primary tumor and has had a successful pregnancy following treatment.
  • CONCLUSION: Adjuvant chemotherapy of ovarian angiosarcoma with a combination of doxorubicin and ifosfamide appears effective and should be considered in women at risk of relapse who wish to conserve fertility.
  • [MeSH-major] Hemangiosarcoma / therapy. Neoplasm Recurrence, Local. Ovarian Neoplasms / therapy. Pregnancy Complications, Neoplastic
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Fertility. Humans. Ifosfamide / administration & dosage. Pregnancy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943995.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 15
  •  go-up   go-down


21. Sessa C, Cresta S, Noberasco C, Capri G, Gallerani E, De Braud F, Zucchetti M, D'Incalci M, Locatelli A, Marsoni S, Corradino I, Minoia C, Zintl P, Gianni L: Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours. Eur J Cancer; 2009 Aug;45(12):2116-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Plasma pharmacokinetics at cycle 1 and a preliminary anti-tumour activity assessment in ovarian and non-small cell lung cancer (OC, NSCLC) were secondary objectives.
  • METHODS: In the dose finding part (DFP) of the study the dose of T given at each administration was escalated by 100 microg/m(2) increments from 300 microg/m(2) up to the MTD, with a fixed dose of C of 40 mg/m(2).
  • T was administered with corticosteroids pre-medication as 3-h infusion and C as 30-min infusion.
  • The MTD of T was 700 microg/m(2) due to dose-limiting neutropaenia and the RDs in the previously treated/untreated patients were 500 and 600 microg/m(2), respectively.
  • Time to recovery from myelosuppression was dose-dependent and treatment could be repeated after > or = 4 weeks in the majority of patients at 600 microg/m(2).
  • Confirmed partial responses were observed in 4 of 13 evaluable OC patients and in 1 with uterine leiomyosarcoma.
  • CONCLUSION: The administration of T and C on days 1 and 8 resulted in prolonged neutropaenia requiring treatment delay.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Non-Small-Cell Lung / drug therapy. Cisplatin / adverse effects. Dioxoles / adverse effects. Lung Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Tetrahydroisoquinolines / adverse effects

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19419856.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dioxoles; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


22. Malagón HD, Valdez AM, Moran CA, Suster S: Germ cell tumors with sarcomatous components: a clinicopathologic and immunohistochemical study of 46 cases. Am J Surg Pathol; 2007 Sep;31(9):1356-62
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The SC included embryonal rhabdomyosarcoma (29), angiosarcoma (6), leiomyosarcoma (4), undifferentiated sarcoma (3), myxoid liposarcoma (1), malignant peripheral nerve sheath tumor (1), malignant "triton" tumor (1), and epithelioid hemangioendothelioma (1).
  • All patients were treated by cisplatinum-based chemotherapy plus other agents followed by surgery.
  • [MeSH-major] Immunohistochemistry. Mediastinal Neoplasms / diagnosis. Neoplasms, Germ Cell and Embryonal / diagnosis. Ovarian Neoplasms / diagnosis. Retroperitoneal Neoplasms / diagnosis. Sarcoma / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Orchiectomy. Ovariectomy. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721191.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Paulino AC, Fowler BZ: Secondary neoplasms after radiotherapy for a childhood solid tumor. Pediatr Hematol Oncol; 2005 Mar;22(2):89-101
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The medical records and radiotherapy charts were reviewed to determine if the patient developed a secondary neoplasm after treatment for malignancy.
  • Twenty-three (5.4%) patients developed a secondary neoplasm.
  • The types of initial solid tumors treated with RT were Ewing sarcoma in 6, Wilms tumor in 6, medulloblastoma in 5, neuroblastoma in 3, and other in 3.
  • Median RT dose was 45 Gy (range, 12.3 to 60 Gy) using 4 MV in 9, 1.25 MV in 8, 250 KV in 4, and 6 MV photons in 1 patient.
  • Fourteen had chemotherapy.
  • For the 14 malignant neoplasms, the median time interval from initial tumor to second malignancy was 10.1 years.
  • The 14 second malignant neoplasms (SMN) were osteosarcoma in 3, breast carcinoma in 2, melanoma in 2, malignant fibrous histiocytoma in 1, dermatofibrosarcoma in 1, leiomyosarcoma in 1, mucoepidermoid carcinoma in 1, colon cancer in 1, chronic myelogenous leukemia in 1, and basal cell carcinoma in 1.
  • The 5- and 10-year overall survival rate after diagnosis of an SMN was 69.2%; it was 70% for children with a SMN at the edge or inside the RT field and 66.7% for those outside of the RT field.
  • The 14 benign neoplasms appeared at a median time of 16.9 years and included cervical intraepithelial neoplasia in 3, osteochondroma in 3, thyroid adenoma in 1, duodenal adenoma in 1, lipoma in 1, cherry angioma in 1, uterine leiomyoma in 1, ovarian cystadenofibroma in 1, and giant cell tumor in 1.
  • More than two-thirds of children with a radiation-induced malignancy are alive 10 years after the diagnosis of a SMN.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15804994.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Veltkamp SA, Meerum Terwogt JM, van den Heuvel MM, van Boven HH, Schellens JH, Rodenhuis S: Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel. Invest New Drugs; 2007 Jun;25(3):279-81
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Arm / pathology. Leiomyosarcoma / drug therapy. Ovarian Neoplasms / drug therapy. Respiratory Distress Syndrome, Adult / chemically induced
  • [MeSH-minor] Aged. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Fatal Outcome. Female. Humans. Middle Aged. Severity of Illness Index. Taxoids / administration & dosage. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):706-11 [16496406.001]
  • [Cites] Cancer. 2006 May 1;106(9):2051-7 [16568459.001]
  • [Cites] Lung Cancer. 2004 Jun;44(3):363-8 [15140550.001]
  • [Cites] Br J Cancer. 2006 Jan 16;94(1):62-8 [16404361.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1706-12 [15117993.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2824-31 [12065559.001]
  • (PMID = 17221305.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down






Advertisement